align sequences protein blast (basic local alignment search tool) Search Results


96
ATCC caption a7 a amino acid sequence alignment
Caption A7 A Amino Acid Sequence Alignment, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/caption a7 a amino acid sequence alignment/product/ATCC
Average 96 stars, based on 1 article reviews
caption a7 a amino acid sequence alignment - by Bioz Stars, 2026-06
96/100 stars
  Buy from Supplier

99
Akoya Biosciences amino acid sequence alignments codex
Amino Acid Sequence Alignments Codex, supplied by Akoya Biosciences, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/amino acid sequence alignments codex/product/Akoya Biosciences
Average 99 stars, based on 1 article reviews
amino acid sequence alignments codex - by Bioz Stars, 2026-06
99/100 stars
  Buy from Supplier

92
Addgene inc lentiviral vector pcdh blast mcs nard gfp lamin
Lentiviral Vector Pcdh Blast Mcs Nard Gfp Lamin, supplied by Addgene inc, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/lentiviral vector pcdh blast mcs nard gfp lamin/product/Addgene inc
Average 92 stars, based on 1 article reviews
lentiviral vector pcdh blast mcs nard gfp lamin - by Bioz Stars, 2026-06
92/100 stars
  Buy from Supplier

86
Brookhaven Instruments protein blast search against brookhaven protein data bank pdb
Protein Blast Search Against Brookhaven Protein Data Bank Pdb, supplied by Brookhaven Instruments, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein blast search against brookhaven protein data bank pdb/product/Brookhaven Instruments
Average 86 stars, based on 1 article reviews
protein blast search against brookhaven protein data bank pdb - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

93
Proteintech immunogen sequences
Immunogen Sequences, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/immunogen sequences/product/Proteintech
Average 93 stars, based on 1 article reviews
immunogen sequences - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

93
Addgene inc pspax2 plasmid constructs
Pspax2 Plasmid Constructs, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pspax2 plasmid constructs/product/Addgene inc
Average 93 stars, based on 1 article reviews
pspax2 plasmid constructs - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

90
GSL Biotech clustal omega algorithm
Protein sequences for novel nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain. Single letter amino acid codes. <t>Clustal</t> <t>Omega</t> algorithm used for alignment. Blue highlights indicate sequence diversity with NIH-CoVnb-112, highlighted in gray, set as the reference sequence for comparison. For comparison, seven previously reported nanobody sequences have clearly distinct sequences: Ty1 , VHH72 , H11-D4 , MR3 , Sb#14 , Sb23 , and W25UACh and possess shorter CDR3 domains (represented in NIH-CoVnb-112 by amino acids 99–120).
Clustal Omega Algorithm, supplied by GSL Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clustal omega algorithm/product/GSL Biotech
Average 90 stars, based on 1 article reviews
clustal omega algorithm - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
ATUM Bio grp94 mc protein domain construct gene
Structural features of and interaction model for <t>Grp94</t> and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.
Grp94 Mc Protein Domain Construct Gene, supplied by ATUM Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/grp94 mc protein domain construct gene/product/ATUM Bio
Average 90 stars, based on 1 article reviews
grp94 mc protein domain construct gene - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

90
CLC Bio clc sequence viewer 6
Structural features of and interaction model for <t>Grp94</t> and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.
Clc Sequence Viewer 6, supplied by CLC Bio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/clc sequence viewer 6/product/CLC Bio
Average 90 stars, based on 1 article reviews
clc sequence viewer 6 - by Bioz Stars, 2026-06
90/100 stars
  Buy from Supplier

86
Biotechnology Information computer program blastp
Structural features of and interaction model for <t>Grp94</t> and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.
Computer Program Blastp, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/computer program blastp/product/Biotechnology Information
Average 86 stars, based on 1 article reviews
computer program blastp - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

93
R&D Systems human vegf165
Structural features of and interaction model for <t>Grp94</t> and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.
Human Vegf165, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human vegf165/product/R&D Systems
Average 93 stars, based on 1 article reviews
human vegf165 - by Bioz Stars, 2026-06
93/100 stars
  Buy from Supplier

86
Biotechnology Information protein blast algorithm
Structural features of and interaction model for <t>Grp94</t> and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.
Protein Blast Algorithm, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/protein blast algorithm/product/Biotechnology Information
Average 86 stars, based on 1 article reviews
protein blast algorithm - by Bioz Stars, 2026-06
86/100 stars
  Buy from Supplier

Image Search Results


Protein sequences for novel nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain. Single letter amino acid codes. Clustal Omega algorithm used for alignment. Blue highlights indicate sequence diversity with NIH-CoVnb-112, highlighted in gray, set as the reference sequence for comparison. For comparison, seven previously reported nanobody sequences have clearly distinct sequences: Ty1 , VHH72 , H11-D4 , MR3 , Sb#14 , Sb23 , and W25UACh and possess shorter CDR3 domains (represented in NIH-CoVnb-112 by amino acids 99–120).

Journal: Scientific Reports

Article Title: High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme

doi: 10.1038/s41598-020-79036-0

Figure Lengend Snippet: Protein sequences for novel nanobodies that bind to the SARS-CoV-2 spike protein receptor binding domain. Single letter amino acid codes. Clustal Omega algorithm used for alignment. Blue highlights indicate sequence diversity with NIH-CoVnb-112, highlighted in gray, set as the reference sequence for comparison. For comparison, seven previously reported nanobody sequences have clearly distinct sequences: Ty1 , VHH72 , H11-D4 , MR3 , Sb#14 , Sb23 , and W25UACh and possess shorter CDR3 domains (represented in NIH-CoVnb-112 by amino acids 99–120).

Article Snippet: Sequences were trimmed to include only the VHH coding region and the protein coding sequences aligned using the Clustal Omega algorithm included in SnapGene software (GSL Biotech LLC).

Techniques: Binding Assay, Sequencing, Comparison

Structural features of and interaction model for Grp94 and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.

Journal: Scientific Reports

Article Title: Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation

doi: 10.1038/s41598-019-48751-8

Figure Lengend Snippet: Structural features of and interaction model for Grp94 and myocilin. ( A ) Model of Grp94 highlighting its structural domains: Pre-N subdomain, cyan; N-terminal ATP-binding domain (N), light blue; middle domain (M), blue; C-terminal dimerization domain (C), purple. The second monomer of the obligate homodimer is shaded gray for clarity. ( B ) Schematic of myocilin structural organization emphasizing the C-terminal olfactomedin (OLF) domain in green. Colored spheres represent calcium (orange) and potassium (magenta) ions. Models are not drawn to scale. Models are from structures with PDB-ID codes 5ULS (Grp94) and 4WXQ, 5VR2 (myocilin). ( C ) Model of Grp94 involvement in myocilin aggregation and glaucoma-associated cellular toxicity. Grp94 is recruited by misfolded, aggregating mutant myocilin via the ERAD system, but counterproductively facilitates aggregation and preserves toxic aggregates; preventing the Grp94/myocilin interaction is a viable method of rescuing cells from cytotoxicity via alternative clearance mechanisms. Myoc = myocilin.

Article Snippet: Grp94 MC protein domain construct gene (residues 336–765, Canis lupus familiaris origin, 98.4% identity to human sequence for Grp94 MC , 97.9% identity overall based on Clustal Omega alignment ) was synthesized and codon-optimized for E . coli expression by ATUM and cloned into a pMAL-c5X vector (New England Biolabs) so that it contained a TEV-cleavable N-terminal maltose binding protein (MBP), and a Factor Xa-cleavable C-terminus 6xHis tag.

Techniques: Binding Assay, Mutagenesis

The N-terminal domain of Grp94 is responsible for the aberrant Grp94/OLF protein-protein interaction. ( A ) Grp94 N enhances the rate of OLF aggregation, whereas Grp94 MC appears to stabilize OLF against aggregation as indicated by ThT fluorescence. Results represent the average of 20 (OLF + Grp94 N ), 12 (OLF + Grp94 NM ), and 12 (OLF + Grp94 MC ) replicates from at least 2 biological replicates. The ^ symbol represents data presented previously ; ***(p < 0.0001) represents statistically significant differences relative to OLF at 24 hours. ( B ) The Grp94 N-terminal domain and OLF co-aggregate over the course of the aggregation assay in ( A ). S = supernatant, W = wash, and P = pellet/aggregate. See Fig. for full four-day kinetics assay data, and Fig. for additional co-aggregation SDS-PAGE gels for the remaining domain constructs.

Journal: Scientific Reports

Article Title: Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation

doi: 10.1038/s41598-019-48751-8

Figure Lengend Snippet: The N-terminal domain of Grp94 is responsible for the aberrant Grp94/OLF protein-protein interaction. ( A ) Grp94 N enhances the rate of OLF aggregation, whereas Grp94 MC appears to stabilize OLF against aggregation as indicated by ThT fluorescence. Results represent the average of 20 (OLF + Grp94 N ), 12 (OLF + Grp94 NM ), and 12 (OLF + Grp94 MC ) replicates from at least 2 biological replicates. The ^ symbol represents data presented previously ; ***(p < 0.0001) represents statistically significant differences relative to OLF at 24 hours. ( B ) The Grp94 N-terminal domain and OLF co-aggregate over the course of the aggregation assay in ( A ). S = supernatant, W = wash, and P = pellet/aggregate. See Fig. for full four-day kinetics assay data, and Fig. for additional co-aggregation SDS-PAGE gels for the remaining domain constructs.

Article Snippet: Grp94 MC protein domain construct gene (residues 336–765, Canis lupus familiaris origin, 98.4% identity to human sequence for Grp94 MC , 97.9% identity overall based on Clustal Omega alignment ) was synthesized and codon-optimized for E . coli expression by ATUM and cloned into a pMAL-c5X vector (New England Biolabs) so that it contained a TEV-cleavable N-terminal maltose binding protein (MBP), and a Factor Xa-cleavable C-terminus 6xHis tag.

Techniques: Fluorescence, SDS Page, Construct

Impact of  Grp94  domains on OLF aggregation.

Journal: Scientific Reports

Article Title: Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation

doi: 10.1038/s41598-019-48751-8

Figure Lengend Snippet: Impact of Grp94 domains on OLF aggregation.

Article Snippet: Grp94 MC protein domain construct gene (residues 336–765, Canis lupus familiaris origin, 98.4% identity to human sequence for Grp94 MC , 97.9% identity overall based on Clustal Omega alignment ) was synthesized and codon-optimized for E . coli expression by ATUM and cloned into a pMAL-c5X vector (New England Biolabs) so that it contained a TEV-cleavable N-terminal maltose binding protein (MBP), and a Factor Xa-cleavable C-terminus 6xHis tag.

Techniques:

Mapping the Grp94/OLF protein-protein interaction interface. ( A ) Coomassie blue (left) and dansyl fluorescence (right) visualization of crosslinking reaction products (arrows) as seen by SDS-PAGE for the coupling of Grp94 NM with OLF. Dashed line distinguishes different visualizations of same gel. See Fig. for complementary reactions with Grp94 N and Grp94 MC . See Fig. for uncropped gel images. ( B ) MS spectrum of crosslinked peptides containing the Grp94 K547 -OLF K468 linkage (top). HCD fragmentation spectrum and fragment mass match accuracy (1 of 9 PSMs observed) with y- and b-ion assignments (inset) consistent with the crosslinked peptides shown (bottom). Data correspond to the sample gel shown in Fig. ; refer to Table for additional details. ( C ) Map of the interaction interfaces between Grp94 and OLF identified by mass spectrometry. Protein domains demarcated by first amino acid residue in the domain (top, Grp94; bottom, OLF). Colors match those of the models in Fig. .

Journal: Scientific Reports

Article Title: Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation

doi: 10.1038/s41598-019-48751-8

Figure Lengend Snippet: Mapping the Grp94/OLF protein-protein interaction interface. ( A ) Coomassie blue (left) and dansyl fluorescence (right) visualization of crosslinking reaction products (arrows) as seen by SDS-PAGE for the coupling of Grp94 NM with OLF. Dashed line distinguishes different visualizations of same gel. See Fig. for complementary reactions with Grp94 N and Grp94 MC . See Fig. for uncropped gel images. ( B ) MS spectrum of crosslinked peptides containing the Grp94 K547 -OLF K468 linkage (top). HCD fragmentation spectrum and fragment mass match accuracy (1 of 9 PSMs observed) with y- and b-ion assignments (inset) consistent with the crosslinked peptides shown (bottom). Data correspond to the sample gel shown in Fig. ; refer to Table for additional details. ( C ) Map of the interaction interfaces between Grp94 and OLF identified by mass spectrometry. Protein domains demarcated by first amino acid residue in the domain (top, Grp94; bottom, OLF). Colors match those of the models in Fig. .

Article Snippet: Grp94 MC protein domain construct gene (residues 336–765, Canis lupus familiaris origin, 98.4% identity to human sequence for Grp94 MC , 97.9% identity overall based on Clustal Omega alignment ) was synthesized and codon-optimized for E . coli expression by ATUM and cloned into a pMAL-c5X vector (New England Biolabs) so that it contained a TEV-cleavable N-terminal maltose binding protein (MBP), and a Factor Xa-cleavable C-terminus 6xHis tag.

Techniques: Fluorescence, SDS Page, Mass Spectrometry, Residue

Model of Grp94 protein-protein interaction sites with OLF. ( A ) Top: structural model of Grp94 highlighting both the aberrant (K72) and stabilizing (K547) interaction sites detected by crosslinking/MS (see Table ). Bottom: electrostatic surface potential view of boxed MC region; Grp94 MC model PDB-ID: 2O1T, which contains 18 additional, largely acidic C-terminal residues compared to 5ULS shown above (also see Fig. ). The proposed OLF recognition surface is identified by dotted circle. ( B ) Top: top-down perspective of OLF β-propeller, with unstructured N-terminal aggregation-associated Grp94 recognition site marked as Nterm*. Middle: side-on view of OLF with stabilizing interaction residue (K468) featured. Bottom: electrostatic surface potential of OLF in same pose as middle panel, indicating a positively-charged surface. The surface potential is colored negative (red, −5 kT/e − ) to positive (blue, 5 kT/e − ). The remaining color scheme and models shown are the same as in (Fig. ) unless otherwise specified.

Journal: Scientific Reports

Article Title: Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation

doi: 10.1038/s41598-019-48751-8

Figure Lengend Snippet: Model of Grp94 protein-protein interaction sites with OLF. ( A ) Top: structural model of Grp94 highlighting both the aberrant (K72) and stabilizing (K547) interaction sites detected by crosslinking/MS (see Table ). Bottom: electrostatic surface potential view of boxed MC region; Grp94 MC model PDB-ID: 2O1T, which contains 18 additional, largely acidic C-terminal residues compared to 5ULS shown above (also see Fig. ). The proposed OLF recognition surface is identified by dotted circle. ( B ) Top: top-down perspective of OLF β-propeller, with unstructured N-terminal aggregation-associated Grp94 recognition site marked as Nterm*. Middle: side-on view of OLF with stabilizing interaction residue (K468) featured. Bottom: electrostatic surface potential of OLF in same pose as middle panel, indicating a positively-charged surface. The surface potential is colored negative (red, −5 kT/e − ) to positive (blue, 5 kT/e − ). The remaining color scheme and models shown are the same as in (Fig. ) unless otherwise specified.

Article Snippet: Grp94 MC protein domain construct gene (residues 336–765, Canis lupus familiaris origin, 98.4% identity to human sequence for Grp94 MC , 97.9% identity overall based on Clustal Omega alignment ) was synthesized and codon-optimized for E . coli expression by ATUM and cloned into a pMAL-c5X vector (New England Biolabs) so that it contained a TEV-cleavable N-terminal maltose binding protein (MBP), and a Factor Xa-cleavable C-terminus 6xHis tag.

Techniques: Residue

The Pre-N region and conformational state of Grp94 N are critical for the aberrant interaction with myocilin OLF. ( A ) Truncation of the N domain of Grp94 eliminates its capacity to enhance the rate of OLF aggregation; residues 22-57 appear crucial to the interaction. Results represent the average of 12 replicates (for both OLF + Grp94 58-804 and OLF + Grp94 73-804 ) from 2 biological replicates. The ^ symbol represents data previously published ; ***(p < 0.0001) represents statistically significant differences relative to OLF + Grp94 FL . ( B ) Despite diminished effects on OLF aggregation, the majority of the Grp94 truncation variant proteins still co-aggregate with OLF. S = supernatant, W = wash, P = pellet/aggregate. ( C ) Treatment of Grp94 N with Grp94-specific inhibitor 4-Br-BnIm mitigates its interaction with OLF. The traces for Grp94 N (for comparison) are the same as in Fig. ; results for OLF + Grp94 N + 4-Br-BnIm represent the average of 9 replicates from 2 biological replicates. ***(p < 0.0001) represents statistically significant differences relative to OLF + Grp94 N . D) Grp94 N is partially rescued from its co-aggregation fate with OLF in the presence of inhibitor 4-Br-BnIm. Abbreviations given in ( B ).

Journal: Scientific Reports

Article Title: Different Grp94 components interact transiently with the myocilin olfactomedin domain in vitro to enhance or retard its amyloid aggregation

doi: 10.1038/s41598-019-48751-8

Figure Lengend Snippet: The Pre-N region and conformational state of Grp94 N are critical for the aberrant interaction with myocilin OLF. ( A ) Truncation of the N domain of Grp94 eliminates its capacity to enhance the rate of OLF aggregation; residues 22-57 appear crucial to the interaction. Results represent the average of 12 replicates (for both OLF + Grp94 58-804 and OLF + Grp94 73-804 ) from 2 biological replicates. The ^ symbol represents data previously published ; ***(p < 0.0001) represents statistically significant differences relative to OLF + Grp94 FL . ( B ) Despite diminished effects on OLF aggregation, the majority of the Grp94 truncation variant proteins still co-aggregate with OLF. S = supernatant, W = wash, P = pellet/aggregate. ( C ) Treatment of Grp94 N with Grp94-specific inhibitor 4-Br-BnIm mitigates its interaction with OLF. The traces for Grp94 N (for comparison) are the same as in Fig. ; results for OLF + Grp94 N + 4-Br-BnIm represent the average of 9 replicates from 2 biological replicates. ***(p < 0.0001) represents statistically significant differences relative to OLF + Grp94 N . D) Grp94 N is partially rescued from its co-aggregation fate with OLF in the presence of inhibitor 4-Br-BnIm. Abbreviations given in ( B ).

Article Snippet: Grp94 MC protein domain construct gene (residues 336–765, Canis lupus familiaris origin, 98.4% identity to human sequence for Grp94 MC , 97.9% identity overall based on Clustal Omega alignment ) was synthesized and codon-optimized for E . coli expression by ATUM and cloned into a pMAL-c5X vector (New England Biolabs) so that it contained a TEV-cleavable N-terminal maltose binding protein (MBP), and a Factor Xa-cleavable C-terminus 6xHis tag.

Techniques: Variant Assay, Comparison